Wedbush Maintains Outperform on CG Oncology, Raises Price Target to $91

Benzinga · 3d ago
Wedbush analyst Robert Driscoll maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $84 to $91.